Caregiver Enhanced Assistance and Support for the Elderly Heart Failure Patient at Hospital Discharge (CEASE-HF)

Overview

Close to ninety percent of older heart failure (HF) patients have some cognitive deficits at hospital discharge which may impact their ability to make effective decisions about their healthcare. However, informal care partners (CPs) may assist in managing HF when provided with appropriate education and support. The goal of this randomized clinical trial (RCT) is to evaluate an intervention which will provide 1) additional teaching on management of HF to the patient and CP following hospital discharge, 2) improved communication with the family physician, 3) a HF decision support tool for oral diuretic management, and 4) a digital talking scale. The investigators believe this intervention will improve outcomes and be cost saving. The investigators hypothesize that enhanced education and support for the CPs to assist older HF patients following hospital discharge, combined with improved communication with family physicians, contact with a HF nurse, and simple decision support tools, will lead to earlier recognition of clinical deterioration, and improved patient outcomes. Innovative and cost-effective approaches to manage HF patients following hospital discharge are urgently needed in Canada.

Full Title of Study: “A Randomized Controlled Trial of Enhanced Caregiver Support Versus Usual Care for Managing Older Heart Failure Patients at Hospital Discharge”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Single (Investigator)
  • Study Primary Completion Date: April 2014

Interventions

  • Other: Standardized Heart Failure Discharge Summary to Primary Care Physicians©
    • At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient’s family physician.
  • Behavioral: Standardized education sessions
    • Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
  • Other: Heart Failure Diuretic Decision Support Tool for Patient Self Management©
    • Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
  • Other: Digital talking scale
    • Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
  • Other: Usual care
    • Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.

Arms, Groups and Cohorts

  • Experimental: Enhanced Caregiver Support with Caregiver
    • Standardized Heart Failure Discharge Summary to Primary Care Physicians© Standardized education sessions Heart Failure Diuretic Decision Support Tool for Patient Self Management© Digital talking scale
  • Other: Usual Care with Caregiver
    • Usual care
  • Experimental: Enhanced Support without Caregiver
    • Standardized Heart Failure Discharge Summary to Primary Care Physicians© Standardized education sessions Heart Failure Diuretic Decision Support Tool for Patient Self Management© Digital talking scale
  • Other: Usual Care without Caregiver
    • Usual Care

Clinical Trial Outcome Measures

Primary Measures

  • Patient self care
    • Time Frame: 3 months
    • Self-Care Heart Failure Index (SCHFI) for patients and caregivers

Secondary Measures

  • Death
    • Time Frame: 3 months
    • Deaths (due to cardiac and non-cardiac causes) during 3 months after hospital discharge
  • Heart failure readmission
    • Time Frame: 3 months
    • Heart failure readmission (>= 24 hour hospital stay including the time spent in the emergency room with clinical evidence of heart failure) during 3 months after hospital discharge
  • Emergency room heart failure visits
    • Time Frame: 3 months
    • Emergency room heart failure visits (< 24 hour hospital stay) during 3 months after hospital discharge
  • Perceived caregiver burden
    • Time Frame: 3 months
    • Modified Oberst Caregiver Burden Scale (CBS)
  • Heart failure knowledge acquisition
    • Time Frame: 3 months
    • Knowledge Acquisition Questionnaire (KAQ) for patients and caregivers
  • Medication adherence
    • Time Frame: 3 months
    • Medication Possession Ratio (MPR)
  • Referral to heart failure clinic or to long-term care
    • Time Frame: 3 months
  • Health beliefs
    • Time Frame: 3 months
    • Health Beliefs Questionnaire (HBQ) for patients and caregivers
  • Depression
    • Time Frame: 3 months
    • Geriatric Depression Scale 8 (GDS-8) for the patient

Participating in This Clinical Trial

Inclusion Criteria

  • Primary diagnosis of Heart Failure (with preserved or impaired left ventricular systolic dysfunction) confirmed with the Boston Criteria >= 5 points – 60 years of age or older Exclusion Criteria:

  • Residence in, or planned discharge to a long-term care facility (LTC) – Life expectancy less than 3 months – Patient transferred to Geriatric Rehabilitation unit – No caregiver – Residence is more than a 30 minute rive from hospital of discharge – Patient refused to participate – Caregiver refused to participate – Patient referred for CV surgery prior to hospital discharge – Patient on IV Lasix at or bumetamide at hospital discharge – Not on PO Lasix at hospital discharge – Patient currently on dialysis – Caregiver unavailable during daytime hours – Caregiver has disability, serious mental illness or cognitive dysfunction – Patient discharged early – Patient enrolled in another randomized controlled trial – Patient expired – Patient and caregiver unable to speak and read English (Patient may be enrolled if nurse can converse minimally with patient and caregiver. S-TOFHLA will not be done for reading comprehension and questionnaires will be administered orally.) – Severe aortic stenosis or severe mitral stenosis

Gender Eligibility: All

Minimum Age: 60 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • McMaster University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Catherine Demers, Associate Professor – McMaster University
  • Overall Official(s)
    • Catherine Demers, MD, MSc, FRCPC, Principal Investigator, McMaster University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.